Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dulaglutide on Major Cardiovascular Events in Type 2 Diabetes
2010-023799-21Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing Dulaglutide 1.5 mg once weekly with Placebo once weekly (2 arms). Started Aug 2011; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2010-023799-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023799-21.